Clinical Trial Update: Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating durvalumab in combination with BCG versus standard BCG therapy for non-muscle-invasive bladder cancer is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin) (Bacillus Calmette-Guérin)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-muscle-invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING